A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of the Safety,Pharmacokinetics, and Pharmacodynamics of ETH-155008, A Dual Inhibitor of CDK4/6 and Pim, in Subjects with Relapsed or Refractory B-cell NHL, CLL/SLL and AML

  • Patil, Sushrut (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

Effective start/end date9/09/2131/12/24


  • Lymphoma
  • B-cell Malignancies
  • Haematological malignancy
  • Clinical trial